What You Need to Know Before Undergoing First-Trimester Down Syndrome Screening

Before undergoing first-trimester or second-trimester prenatal screening—commonly referred to as “Down syndrome screening” or “trisomy screening”—several important considerations help ensure accurate and clinically meaningful results.

Timing is critical: the optimal window for combined first-trimester screening (which includes nuchal translucency ultrasound and maternal serum markers PAPP-A and free β-hCG) is between 11 weeks and 13 weeks + 6 days of gestation. For the traditional quad screen—measuring AFP, hCG, unconjugated estriol, and inhibin A—the recommended timeframe is 15 to 22 weeks, with peak sensitivity at 16–18 weeks.

Patient preparation varies by test type. Fasting is not required for either screening protocol. However, accurate gestational dating—confirmed via early ultrasound—is essential, as miscalculation can significantly skew risk calculations. Maternal weight, race, and diabetic status must be documented, as these factors influence biomarker interpretation and risk modeling.

It’s vital to recognize that these screenings are risk-assessment tools—not diagnostic tests. A “screen-positive” result indicates elevated statistical risk and warrants discussion of confirmatory diagnostics, such as cell-free DNA testing (cfDNA), chorionic villus sampling (CVS), or amniocentesis. Conversely, a “screen-negative” result does not guarantee absence of chromosomal abnormalities or other structural anomalies.

Pre-test counseling should address limitations, detection rates (approximately 82–87% for trisomy 21 with first-trimester combined screening; ~80% with the quad screen), and false-positive rates (~5%). Patients should also understand that screening assesses only select aneuploidies—primarily trisomies 21, 18, and 13—and neural tube defects (via AFP in the quad screen)—not all genetic or congenital conditions.